STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.
about
Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of IkarosDOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationDual effect of oxidative stress on leukemia cancer induction and treatmentInhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.Signal transducer and activator of transcription 3 (STAT3) regulates collagen-induced platelet aggregation independently of its transcription factor activity.SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.Co-occurring protein phosphorylation are functionally associated.Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevanceElevated mitochondrial superoxide disrupts normal T cell development, impairing adaptive immune responses to an influenza challenge.Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATORMutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.Suofu Qin's work on studies of cell survival signaling in cancer and epithelial cells.Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in MiceCD22ΔE12 as a molecular target for RNAi therapy.Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in MiceSyk Is Recruited to Stress Granules and Promotes Their Clearance through Autophagy.Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemiaTargeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis.Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.The Syk kinase as a therapeutic target in leukemia and lymphoma.Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Genetic Interactions of STAT3 and Anticancer Drug Development.An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case reportComputational Search for Possible Mechanisms of 4-Thiazolidinones Anticancer Activity: The Power of Visualization.Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.Nanoparticle Formulation to Improve the Efficacy of Radiation Therapy Against Radiation-resistant Leukemia.DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
P2860
Q24301012-A7AF9BD1-3A28-4BFD-A35B-3C5375B7A2A5Q24321675-31FCB12B-F58D-4F7F-9BFB-328461B08732Q26866544-5BB7C9AD-9C11-4764-A88F-127B62F64ED5Q27853177-EC1A16A7-6321-442E-A024-064B92EF0BE0Q30654857-ACFDD1CD-D91F-4F48-A7CB-B8E19904BBA8Q33631405-72FE45E0-8C8D-4B5A-B615-44D197C5E0F9Q33688357-7D7F7584-A5AC-40B9-B063-6CDFD531E379Q34042407-43B9C41C-F083-4A01-98D9-C410075E72D8Q34154532-42A7D25D-069B-4BA5-A24D-428C2F06CB45Q34424343-D892CA84-A5F4-43DB-BA53-17D701CF5525Q34516742-331392EE-5080-4EAB-A258-A61AA2AC527DQ34625171-8624F78C-8115-4FC8-86DD-4F87DFDF929BQ34653474-42642F87-6AA7-4485-937C-B70551D3223AQ34755642-F665DA97-C73C-4FC6-84A6-A857D0BB2D53Q34878598-A0E267D2-5588-4441-B63D-754C7A5EC491Q35183874-D3ECE326-F328-4F6B-A494-6DB7B018B998Q35747708-1708DD48-048F-4692-B7FF-D6FCC2806F2FQ35801180-A49713E6-C7EC-4F13-AE4C-328E2C741A88Q35949248-6DD3FAB2-1CBB-4930-8C73-6553EA66B028Q36282920-E66B4879-EFC8-4FAB-BF9C-65B2B20023CEQ36873283-25DE0CCB-372F-4B03-8066-9BD95F1C74D2Q36889248-0AFAEDC1-11C5-40FF-BCAF-4B3BE5436B79Q36962815-22352D7D-D3E9-46BA-A736-DA77FAF746CBQ37706530-3DF95149-DE0E-47B1-907C-57AED01BC032Q37721603-6940064A-FA4B-4FDF-9F68-17F8DEFD3C5BQ37788239-DE57F4EF-596B-45CC-8EFF-C0AC9F581916Q37857853-AB5EC368-369A-4460-AF6C-2355E9EDB423Q38011765-5126CBD2-0FEE-4A80-9EAD-9D7FB3899FE1Q38097334-8CEB571C-E57D-4FCA-98C2-D6771CEECFBAQ38198930-1E1AC26C-64C1-4D66-BB99-E6DD28A26594Q38741291-07E80CC1-5A68-48ED-B1FF-1589DA9A271AQ38859330-3AF53985-9613-467D-898A-67D323BEB792Q39020380-9BC82080-103D-4151-9AA2-F1C6890B1E93Q42182953-898EA301-EA46-4879-A2CF-28CA6517D389Q42508790-74684503-5F0C-4065-81FF-B39C3FE9169CQ45914413-47DABDA7-1AE6-4269-B1B5-D64BE9D7CC82Q46129905-100A5775-325D-4920-98BB-47F87F52B914Q46134516-AF87D189-3657-499F-927D-F48D18FDE1C0Q47163960-E8DC653F-62A2-479A-A08C-3EAA25970BEBQ51136450-BE44567F-2C16-4204-AC6F-82E093542BEC
P2860
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@ast
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@en
type
label
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@ast
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@en
prefLabel
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@ast
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@en
P2093
P2860
P921
P356
P1476
STAT3 is a substrate of SYK ty ...... s exposed to oxidative stress.
@en
P2093
Lisa Tuel-Ahlgren
Sanjive Qazi
Zahide Ozer
P2860
P304
P356
10.1073/PNAS.0909086107
P407
P577
2010-01-29T00:00:00Z